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Abstract
Background: A common characteristic of allergens is that they contain proteases that can activate protease-
activated receptor (PAR-2); however the mechanism by which PAR-2 regulates allergic airway inflammation is unclear.
Methods: Mice (wild type and PAR-2-deficient) were sensitized using German cockroach (GC) feces (frass), the
isolated protease from GC frass, or through adoptive transfer of GC frass-treated bone marrow-derived dendritic cells
(BMDC) and measurements of airway inflammation (cellular infiltration, cytokine expression, and mucin production),
serum IgE levels and airway hyperresponsiveness (AHR) were assessed. BMDC were cultured, treated with GC frass
and assessed for cytokine production. PAR-2 expression on pulmonary mDCs was determined by flow cytometry.
Results: Exposure to GC frass induced AHR and airway inflammation in wild type mice; however PAR-2-deficient
mice had significantly attenuated responses. To directly investigate the role of the protease, we isolated the
protease from GC frass and administered the endotoxin-free protease into the airways of mice in the presence of
OVA. GC frass proteases were sufficient to promote the development of AHR, serum IgE, and Th2 cytokine
production. PAR-2 expression on mDC was upregulated following GC frass exposure, but the presence of a
functional PAR-2 did not alter antigen uptake. To determine if PAR-2 activation led to differential cytokine
production, we cultured BMDC in the presence of GM-CSF and treated these cells ex vivo with GC frass. PAR-2-
deficient BMDC released significantly less IL-6, IL-23 and TNFa compared to BMDC from wild type mice, suggesting
PAR-2 activation was important in Th2/Th17 skewing cytokine production. To determine the role for PAR-2 on
mDCs on the initiation of allergic airway inflammation, BMDCs from wild type and PAR-2-deficient mice were
treated in the presence or absence of GC frass and then adoptively transferred into the airway of wild type mice.
Importantly, GC frass-stimulated wild type BMDCs were sufficient to induce AHR and allergic airway inflammation,
while GC frass-stimulated PAR-2-deficient BMDC had attenuated responses.
Conclusions: Together these data suggest an important role for allergen activation of PAR-2 on mDCs in
mediating Th2/Th17 cytokine production and allergic airway responses.
Introduction
It is generally accepted that allergic asthma results from
an inappropriate Th2-dominated immune response to an
otherwise innocuous protein. Allergens are derived from
a number of sources, including plants (grasses and trees),
arthropods (mite and cockroach), animals (cats, dogs),
and fungi. While allergens are from diverse sources, a
common characteristic of allergens is that they contain
intrinsic protease activity, or are presented in the airways
along with particles that contain protease activity. For
example, German cockroach (GC) contains serine pro-
teases [1], while HDM contains both the cysteine
protease Der p1 [2,3] and serine proteases Der p3 and
Der p9 [4]. In addition, fungal extracts of Alternaria
alternate and Cladosporium herbarum [5], as well as the
cat allergen Felis domesticus (Fel d 1) [6] contain proteo-
lytic activity. We recently showed that the active serine
proteases in GC feces (frass) played a role in regulating
airway hyperresponsiveness (AHR) to acetylcholine and
mucin production in a mouse model of allergic airway
inflammation [7]. In addition, removal of proteases from
either A. fumigatus [8], American cockroach Per a 10
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purpurascens [10]or Cur 11 antigen from the mold
Curvularia Iunata [11] decreased airway inflammation
and airway hyperresponsiveness in mouse models. To
date, the mechanism(s) by which proteases mediate their
effects is unclear.
Allergen-associated proteases are thought to regulate bio-
logical effects through the activation of protease-activated
receptors (PARs). PARs (-1, -2, -3, -4) are a family of pro-
teolytically activated G-coupled receptors which, when acti-
vated, initiate a signal transduction pathway leading to
transcriptional regulation. Of particular interest is PAR-2,
which has been implicated in allergic diseases. To date,
o n l yaf e ws t u d i e sh a v ei n v e s tigated the importance of
PAR-2 in modulating allergic airway disease. In studies in
which systemically-induced (OVA bound to alum adminis-
tered by intraperitoneal injection) airway responses were
compared in wild type and PAR-2-deficient mice, PAR-2-
deficient mice had decreased cellular infiltration compared
to controls [12]. They also showed that sensitization and
challenge of PAR-2 overexpressing mice with OVA resulted
in increased AHR compared to wild type mice [12]. Since
OVA does not contain protease activity, this study
addressed the role of endogenous proteases (i.e. mast cell
tryptase) released following an initial inflammatory event.
We recently confirmed a role for PAR-2 in mediating aller-
gen-derived allergic airway inflammation [13]; however the
mechanism by which PAR-2 regulated these events is
currently unclear.
Dendritic cells (DC) are the most potent antigen pre-
senting cells and are thought to bridge innate and adaptive
immunity. Mucosal DCs form a dense network associated
with the airway epithelium and can form long extensions
into the airway lumen [14]. To date, little is known regard-
ing the role of proteases or PAR-2 in activating DCs. One
report showed that serine protease activation of PAR-2 sti-
mulated the development of DCs from bone marrow pro-
genitor cells [15]. Thus it is possible that protease
activation of PAR-2 may be important for DC maturation,
thus promoting DC’s to switch from a sentinel, antigen-
capturing mode to a mature antigen-presenting mode.
Recent evidence suggests that specific subsets of DCs are
critical not only for the initiation of allergic airway
responses, but also to drive immunity (myeloid, mDC) or
tolerance (plasmacytoid, pDC) [16-18]. To date, it is
unclear how these subsets are regulated in the airways.
Interestingly, uptake of Alexa Fluor 488-labeled OVA by
DCs was enhanced when PAR-2 was activated using a
selective PAR-2 agonist [19]. Clearly, protease-PAR-2 may
play an important, yet undefined, role in the regulation of
DC maturation, function, and activation.
In this report we investigate the role of PAR-2 in med-
iating the development of allergen-induced allergic air-
way inflammation through the activation of DCs. We
confirmed the importance of functional PAR-2 for aller-
gic airway inflammation and show that the isolated
protease from GC frass was sufficient to induce AHR,
increased serum IgE and a Th2 skewing phenotype when
in the presence of OVA. We found that GC frass upregu-
lated PAR-2 expression on pulmonary mDCs but failed
to detect PAR-2 on pDCs. While we failed to find differ-
ences in uptake of allergen in the PAR-2-deficient mice,
there was a considerable difference in T cell skewing
cytokine production in the PAR-2-deficient BMDC.
Finally, we confirmed that GC frass activation of wild
type BMDC was sufficient to induce AHR and airway
inflammation; however this response was partially depen-
dent on a functional PAR-2 on the BMDC. These data
suggest the importance of protease-PAR-2 activation of
the DC in the regulation of allergic airway responses.
Materials and methods
German cockroach frass
The fecal remnants (frass) from one cage of German cock-
roaches were transferred to a sterile container and stored
at 4°C. Frass were resuspended in endotoxin-free double-
distilled water (2 h at 4°C while rocking). Extracts were
centrifuged to remove debris (10,000 g for 10 min at 4°C),
supernatants harvested, and total protein was measured
using the Bio-Rad Protein Assay Dye (Bio-Rad, Hercules,
CA). GC frass was frozen in aliquots for use throughout
the entire study. AlexaFluor-405 (Invitrogen, Carlsbad,
CA) labeled GC frass (AF405-GC frass) was made accord-
ing to manufacturers’ specifications.
Protease-enhancement of GC frass
GC frass was run through a size exclusion column
(Sephadex G75 superfine, Amersham Pharmacia, Piscat-
away, NJ) and the fractions in the protease-containing
peak were combined and run through a prepacked
HiTrap Benzamidine FF affinity column (GE Healthcare,
Piscataway, NJ). Serine proteases bind this column and
are eluted using a buffer containing 20 mM para-amino-
benzamidine (Spectrum Chemical Corp, Gardenia, CA).
The fractions containing protease activity were combined,
dialyzed against ddH2O and measured for protein con-
centration and protease activity as previously described
[20]. Information regarding the amount of protein, enzy-
matic activity and endotoxin in the starting material GC
frass and in the final column-purified protease sample is
shown elsewhere [20]. The protease-enhanced GC frass
was frozen in aliquots and used for the remainder of the
studies.
Animals and GC frass exposure
BALB/c and PAR-2-deficient mice were obtained from
Jackson Laboratory (Bar Harbor, ME). PAR-2-C57Bl/6
mice were backcrossed for 10 generations onto the
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experiments, mice (6-8 weeks old) were anesthetized
with ketamine (45 mg/kg)/xylazine (8 mg/kg) prior to
inhalation of PBS (40 μl), LPS-free ovalbumin (OVA;
100 μg/mouse; Worthington Biochem Corp, Lakewood
NJ), OVA (100 μg) plus enriched protease (0.5 units), or
OVA (100 μg) plus LPS (0.1 μg/mouse; Sigma Chemical
Corp, St. Louis MO #055:B5) on day 0, 14, and 21 [21].
Mice were harvested on Day 24. For the adoptive trans-
fer of bone marrow-derived DCs (BMDC), 40 μlo f
BMDC (1 × 10
6 cells) suspension was administered via
instillation into the airways of anesthetized mice. 14 d
later, mice were exposed to a single intratracheal inhala-
tion of either PBS (40 μl) or GC frass (40 μg/40 μl). In all
cases, 72 h following the final inhalation, airway
responses were measured. For flow cytometry studies, a
single exposure to PBS or GC frass was followed by a
lethal dose of sodium pentobarbital 20 h later. These stu-
dies were approved by the Cincinnati Children’s Hospital
Medical Center Institutional Animal Care and Use
Committee.
Airway hyperresponsiveness measurements
Allergen-induced airway hyperresponsiveness (AHR) was
determined as we have previously described [22]. Briefly,
mice were anesthetized 72 h after the last GC frass expo-
sure, intubated and ventilated at a rate of 120 breaths per
minute with a constant tidal volume of air (0.2 ml), and
paralyzed with decamethonium bromide (25 mg/kg).
After establishment of a stable airway pressure, 25 μg/kg
weight of acetylcholine was injected i.v. and dynamic
airway pressure (airway pressure time index [APTI] in
cm-H2O × sec
-1) was followed for 5 min.
Assessment of airway inflammation
Lungs were lavaged with 1 ml of Hanks balanced salt
solution without calcium or magnesium. The lavage fluid
was centrifuged (1,800 rpm for 10 min), the supernatant
was removed for cytokine analysis and immediately
stored at -80°C. Total cell numbers were counted on a
hemocytometer. Smears of BAL cells prepared with a
Cytospin II (Shandon Thermo, Waltham, MA) were
stained with Diff-Quick (Thermo Electron Corporation,
Pittsburg, PA) solution for differential cell counting.
Serum IgE
Animals were bled and serum isolated for total IgE
levels using antibodies from BD Biosciences (San
Diego, CA).
Cytokine production
Liberase/DNase I digests of the lung were prepared to
obtain single lung cell suspensions. Single cell suspensions
(2.5 × 10
5) were incubated for 72 hours in culture medium
(RPMI) or in RPMI treated with GC frass (1 μg/ml) or
ConA (10 μg/ml) and supernatants were analyzed by
ELISA for Th2 cytokine expression as previously described
[21].
ELISAs
All ELISAs were from R&D Systems (Minneapolis, MN)
and run according to manufacturer’s specifications.
Histology
Whole lungs were removed and formalin fixed. Lungs
were embedded in paraffin, sectioned, and stained with
haematoxylin and eosin (H&E) and Periodic Acid Schiff
(PAS).
Flow cytometry
Whole lungs were isolated from mice 20 h following
exposure, minced and placed in RPMI 1640 containing
Liberase CI (0.5 mg/ml; Roche Diagnostics, Indianapolis,
IN) and DNase I (0.5 mg/ml; Sigma, St. Louis MO) at
37°C for 45 minutes. The tissue was forced through a 70-
micron cell strainer, and red blood cells were lysed with
ACK lysis buffer (Invitrogen, Carlsbad, CA). Cells were
washed with RPMI containing 10% FBS, counted and pla-
ted at 500,000 cells per well in a 96 well plate. Staining
reactions were performed at 4°C following incubation
with Fc block (mAb 2.4G2) for 30 min. Myeloid DCs
(CD11c
+, CD11b
+,G r 1
neg, CD317
neg) and plasmacytoid
DCs (CD11c
+, CD11b
neg,G r 1
low,C D 3 1 7
+)w e r eq u a n t i -
fied using anti-CD11c-APC (HL3), anti-CD11b-PE-Cy7
(M1/70), and anti GR-1-APC-Cy7 (RB6-8C5). PAR-2
expression was examined using a PE-conjugated mAb to
PAR-2 (Santa Cruz, Santa Cruz, CA). Co-stimulatory
molecule expression was examined using PE-conjugated
mAbs to CD86 (GL1) or CD80 (16-10A1). Dead cells
were excluded using 7-AAD. All antibodies (with the
exception of PAR-2) were purchased from eBioscience
(San Diego, CA). Data were acquired with an LSRII flow
cytometer (BD Biosciences, San Jose, CA). Spectral over-
lap was compensated using the FACSDiVa software (BD
Biosciences) and analyzed using FlowJo software (Trees-
tar Inc, Ashland, OR).
Isolation and development of mature, GC frass-pulsed
bone marrow-derived myeloid DCs
Mice were given a lethal dose of sodium pentobarbital
prior to removal of tibias and femurs. Bone marrow
cells (1.5 × 10
7 cells per ml) were cultured on complete
RPMI supplemented with GM-CSF (10 ng/ml, Pepro-
tech, Rocky Hills, NJ). Fresh media was added along
with GM-CSF (10 ng/ml) on day 3. On day 6, cells were
treated with endotoxin-free PBS or GC frass (1 μg/ml)
for 24 h. Cells were washed, counted and resuspended
at 2.5 × 10
6 cells/ml.
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RNA was extracted using a standard TRIzol method of
phenol extraction. Total RNA is converted to cDNA by
reverse transcription using the Superscript First Strand
Synthesis System kit (Invitrogen, Carlsbad, CA). The PAR-
2 primers are 5’-CTTAGCCTTCTTGCCAGGTG-3’ and
5’-TCTCTGCACCAATCACAAGC-3’ and the b-actin pri-
mers are 5’-TGTTACCAACTGGGACGACA-3’and 5’-
GGGGTGTTGAAGGTCTCAAA-3’. Amplification was
performed by PCR using SYBR Green on the iCycler
(BioRad Laboratories) as follows: 1 cycle 95°C for 3 min,
followed by 40 cycles of [95°C for 5 sec, 57°C for b-actin
and 60°C for PAR-2 for 5 sec, 72°C for 10 sec], 95°C for
1 min, 55°C for 1 min and then a hold of 25°C. The target
gene is normalized to the reference gene using the Pfaffl
method [23].
Statistical analysis
When applicable, statistical significance was assessed by
Students t-test or one-way analysis of variance (ANOVA).
Differences identified by ANOVA were pinpointed by Stu-
dent-Newman-Keuls’ multiple range test using SigmaStat
software.
Results
PAR-2 promotes the development of GC frass-induced
asthma
To determine the role of PAR-2 in mediating allergen-dri-
ven AHR, wild type and PAR-2-deficient mice were
exposed to GC frass by intratracheal instillation on day 0
and 14, and three days later airway responses were mea-
sured. Exposure of wild type mice to GC frass resulted in
increased AHR which was significantly attenuated in PAR-
2-deficient mice (Figure 1A). Next we cultured cells from
whole lungs and re-stimulated the cells with GC frass to
assess the ability of GC frass to induce cytokine produc-
tion. GC frass induced production of the Th2 cytokines
IL-5 (Figure 1B), IL-13 (Figure 1C) and IL-4 (data not
shown) and the Th17 cytokine IL-17A (Figure 1D). Impor-
tantly, PAR-2-deficient mice had significantly reduced
Figure 1 Reduced allergen-induced AHR in PAR-2-deficient mice. BALB/c or PAR-2 -/- mice were treated with PBS or GC frass (40 μg/40 μl)
GC frass on days 0 and 14. Mice were sacrificed on Day 17. In all cases the data are expressed as mean ± SEM and represent 4-6 mice per
group and statistical significance determined by ANOVA (in all cases * p < 0.001, **p < 0.05). A. AHR was measured as airway pressure time
index (APTI) in cm-H2O × sec
-1. B-D. Lungs from the mice were excised; cells dissociated and maintained in a single suspension culture for 3
days in the presence of GC frass (1 μg/ml). B. IL-5 levels. C. IL-13 levels. D. IL-17A levels.
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exposure also induced a significant increase in eosinophilia
and neutrophilia into the BAL fluid of wild type mice, and
this was also significantly reduced in the PAR-2-deficient
mice (Table 1). Together these data suggest an important
role for PAR-2 in regulating allergic airway inflammation.
GC frass protease strongly promotes the development of
Th2 immunity
GC frass is a complex mixture containing both active ser-
ine proteases, and TLR4 agonists, such as LPS. Both active
protease from Aspergillus fumigatus [8] and LPS (0.1 μg)
[24] have been shown to enhance Th2 sensitization to a
normally tolerogenic antigen (OVA). As such, we wished
to determine the relative importance of GC frass-derived
serine proteases and LPS in driving Th2 response observed
following GC-frass sensitization and challenge. We have
previously reported the enrichment of the active serine
protease from GC frass which significantly increased the
amount of protease and almost completely removed endo-
toxin (~1 pg/μg protein) [20]. Thus, to test whether GC
frass-derived protease acted as an adjuvant for specific
Th2 sensitization in the induction of allergic airway
responses, we sensitized and challenged mice with OVA,
OVA in the presence of GC-frass derived protease,
or OVA in the presence of LPS (0.1 μg) on Days 0, 14
and 21. Importantly, while OVA itself failed to induce sig-
nificant AHR, Th2, or Th17 cytokine production, OVA
containing protease was sufficient to induce airway
responsiveness to cholinergic agents (Figure 2A), increase
serum IgE levels (Figure 2B), and induce the whole lung
production of theTh2 cytokines IL-5 (Figure 2C), IL-13
(Figure 2D) and IL-4 (data not shown) alone or in the pre-
s e n c eo fC o n A .I L - 1 7 A( F i g u r e2 E )a n dI F N g (Figure 2F)
levels were unaltered by the protease. Thus, the principal
effect of the protease is to enhance the development of
Th2 immunity. In contrast, while the presence of LPS
moderately enhanced AHR (Figure 2A), serum IgE levels
(Figure 2B) and Th2 cytokine production (Figure 2C, D), it
markedly enhanced production of IL-17A (Figure 2E) and
IFNg (Figure 2F), suggesting that LPS is capable of
enhancing Th2, Th7 and Th1 responses. Together, these
data support the observation that the active serine pro-
teases in GC frass are sufficient to induce robust Th2
responses following mucosal allergen exposure in mice.
PAR-2 is expressed on pulmonary mDCs and is regulated
by allergen exposure
As uptake of allergen by pulmonary DCs is required for
optimal stimulation of T cell responses leading to
asthma, and both PAR-2 and active serine proteases are
effective at enhancing Th2 responses in vivo,w ew i s h e d
to determine if PAR-2 could be detected on the surface
of pulmonary mDCs. To this end, wild type mice were
exposed to a single intratracheal inhalation of PBS or GC
frass. Twenty hours later, whole lungs were harvested,
dissociated and stained for flow cytometric analysis of
PAR-2 expression on pulmonary DCs. PAR-2 expression
was apparent on neutrophils (data not shown); however
PAR-2 expression on pulmonary mDCs and pDCs could
not be reliably detected in naïve mice. Importantly, inha-
lation of GC frass induced the expression of PAR-2 on
the pulmonary mDCs (Figure 3A, B) but not on pDCs
(data not shown). This suggests the upregulation of PAR-
2 on mDCs but not pDCs following allergen exposure.
One possibility for the decreased allergic airway
inflammation in PAR-2 could be differential uptake of
allergen in DCs between wild type and PAR-2-deficient
mice. To address this, wild type or PAR-2-deficient
mice were exposed to a single intratracheal inhalation of
PBS or Alexa405-labeled (AF405) GC frass. Twenty-four
hours later, whole lungs were harvested, dissociated and
stained for flow cytometry. We found no difference in
the percentage (Figure 3C) of AF405-GC frass positive
mDCs or in the MFI (Figure 3D) between wild type and
PAR-2-deficient mice exposed to the allergen. Taken
together these data demonstrate that while PAR-2
expression is enhanced on pulmonary mDCs after GC
frass exposure, it does not mediate its Th2-enhancing
properties by enhancing antigen uptake by pulmonary
mDC.
Differential cytokine production from PAR-2-deficient
BMDCs
To better delineate the importance of PAR-2 expression
on the activity of mDCs, we cultured BMDCs from WT or
PAR-2-deficient mice with GC frass for 18 hours and cyto-
kine expression was measured by ELISA. BMDCs were >
90% mDCs as characterized by flow cytometry (CD11b
+
CD11c
+ Gr1
neg CD317
neg; data not shown). As observed
on pulmonary mDCs from in vivo GC frass treated mice,
we also observed that PAR-2 expression was induced by
GC frass exposure in BMDCs (Figure 4A). GC frass
increased cytokine expression from wild type and PAR-2-
deficient mDC; however the levels of IL-6 (Figure 4B),
Table 1 Differential cell count in BAL fluid of wild type
and PAR-2-deficient mice
Mac Epi Eos Neut Lymph
BALB/c PBS 1.4 ± 0.2 1.7 ± 0.4 0 0.04 ± 0.02 0.09 ± 0.05
PAR2-/- PBS 1.6 ± 0.3 3.5 ± 1.6 0 0.02 ± 0.02 0.07 ± 0.03
BALB/c frass 8.6 ± 3.6 5.2 ± 1.6 1.7 ± 0.5 4.4 ± 0.7 * 1.6 ± 0.04
PAR2-/- frass 3.4 ± 1.1 4.0 ± 1.5 0.6 ± 0.3 † 1.2 ± 0.02 † 1.5 ± 0.8
BALB/c and PAR-2-/- mice were challenged by intratracheal inhalation on Day
0 and 14 with PBS or GC frass (40 μg). On day 17, BAL fluid was harvested
and differential cell counts performed. These data represent 4-6 mice per
group and are expressed as mean ± SEM of cell number × 10
3. Cell counts
were statistically significant between GC frass and PBS exposed mice
(*p < 0.05) and between BALB/c and PAR-2-/- mice (†p < 0.05).
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OVA, OVA plus enriched GC frass protease (OVA+protease) or OVA plus LPS (0.1 μg LPS; OVA+LPS) on Days 0, 7, and 14. On day 17, mice were
anesthetized and acetycholine was injected after establishment of a stable airway pressure. In all cases the data are expressed as mean ± SEM (n
= 4-6 mice per group) and statistical significant was determined by ANOVA. A. AHR was measured as airway pressure time index (APTI) in cm
H2O × sec
-1 (*p < 0.001 **p = 0.015). B. Serum IgE levels were measured by ELISA (*p < 0.05). Lungs from mice were excised, cells dissociated
and maintained in a single suspension culture for 3 days unstimulated or in the presence of ConA (10 μg/ml). Cell supernatants were collected,
clarified and analyzed by ELISA (in all cases, *p < 0.001 and ** p < 0.05). C. IL-5 levels. D. IL-13 levels. E. IL-17A levels. F. IFNg levels.
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cient mDCs were significantly lower than in wild type
mDCs. The levels of IL-12 and IL-10 were not above the
level of detection of the assay (data not shown). To con-
firm that PAR-2-deficient mDCs are capable of producing
high levels of cytokines, we treated cells with the TLR2
agonist, Pam3Cys. There was no difference between the
wild type and PAR-2-deficient mDC in their response to a
TLR2 agonist. These data suggest that activation of PAR-2
plays a role in enhancing the ability of mDCs to produce
T cell skewing cytokines following exposure to protease-
containing allergens.
Regulation of co-stimulatory molecule expression on mDC
To further explore alterations in PAR-2-deficient mDC,
we investigated the regulation of the co-stimulatory
molecules CD80 and CD86 on the lung mDC population
following GC frass inhalation. BALB/c and PAR-2-defi-
cient mice were exposed to PBS or GC frass and 20 h
later, whole lungs were harvested, dissociated and stained
for flow cytometric analysis of CD80 and CD86 expres-
sion. GC frass increased expression of both CD80 and
CD86 on mDC following a single exposure (Figure 5).
There was no difference in the levels of CD80 or CD86
staining on mDCs from PBS-treated PAR-2-deficient
mice compared to wild type mice, suggesting that PAR-
2-deficient mice do not have inherent alterations in DC
activation. Interestingly, following GC frass exposure, the
number of CD86 and CD80 molecules (as indicated by
MFI) on the cell surface of mDCs in PAR-2-deficient
mice was less compared to wild type mice (Figure 5A
and 5C). There was a significant difference in percentage
of mDC expressing CD80 in the PAR-2-deficient mice
compared to wild type (Figure 5B), however there was no
Figure 3 Frass treatment increased expression of PAR-2 on pulmonary myeloid dendritic cell. Lungs from PBS or GC frass-treated mice
were harvested 20 h post exposure and stained for flow cytometric analysis of PAR-2 expression. A. Representative histogram showing PAR-2
expression on gated pulmonary mDCs from PBS-treated (solid line) or GC frass-treated (dashed line) mice. Solid grey histogram depicts staining
with isotype control mAb. B. Average PAR-2 MFI on gated pulmonary mDCs. Data are expressed as Mean ± SEM (n = 6 mice per group) and
statistical significance determined by ANOVA (*p < 0.001). C +D. AF405-labeled GC frass was instilled in the airways of wild type or PAR-2-/- mice
and 20 h post exposure lungs were isolated and stained for flow cytometry. C. Percent of AF405-positive mDC in the lung (*p < 0.05). D. Mean
fluorescence intensity (MFI) of AF405 in mDCs (*p < 0.05).
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between the two strains of mice (Figure 5D). This data
demonstrates an overall decrease in the levels of CD80
and CD86 on mDCs in PAR-2-deficient mice and sug-
gests that pulmonary mDCs from PAR-2-deficient mice
have reduced activation and capacity for T cell stimula-
tion following allergen sensitization.
Adoptive transfer of PAR-2-deficient BMDC into wild type
mice fails to induce allergic airway inflammation
To further explore the role of PAR-2 on mDCs in promot-
ing the development of allergic airway inflammation, we
performed an adoptive transfer. To this end, BALB/c
BMDCs were treated with PBS or GC frass in vitro for 18
hours and then 1 × 10
6 cells were adoptively transferred
into the lungs of naïve BALB/c mice. Fourteen days later,
mice were challenged with intratracheal inhalation of PBS
or GC frass and airway responses were measured 72 h
post challenge. Adoptive transfer of GC frass-pulsed wild
type BMDCs induced AHR to acetylcholine challenge
(Figure 6A) and increased IL-5 (Figure 6B), IL-13 (Figure
6C), IL-17A (Figure 6D), and IFNg (Figure 6E) compared
to PBS-pulsed wild type BMDCs. Thus, sensitization with
GC-frass pulsed DCs induced a mixed Th1/Th2/Th17
profile similar to that observed in mice sensitized with
HDM-pulsed DCs [18], and reminiscent of the profile
observed in humans with more severe disease [25-28].
Importantly, adoptive transfer of GC frass-pulsed PAR-2-
deficient BMDCs resulted in significantly reduced levels of
AHR (Figure 6A). In addition, the restimulation of the
lungs with GC frass in vitro resulted in up to 50% reduc-
tion in levels of Th2 cytokines (Figure 6B, C). While Th17
Figure 4 GC frass-induced PAR-2 mRNA and cytokine production from BMDC.A .B o n em a r r o ww a si s o l a t e df r o mB A L B / cm i c ea n d
cultured in the presence of GM-CSF for 6 days. Cells (5 × 10
6) were cultured in the presence or absence of GC frass (1 μg/ml) for 4 h. Cells
were extracted in TRIzol, RNA was synthesized and converted to cDNA. Quantitative real time PCR was performed. PAR-2 was normalized to
b-actin and levels are expressed as fold-increase over control (mean ± SEM for 4 separate experiments; *p < 0.001). B-D. Bone marrow was
isolated from BALB/c and PAR-2-deficient mice and was cultured in the presence of GM-CSF for 6 days. Cells (1 × 10
6) were cultured in the
presence or absence of GC frass (1 μg/ml) or Pam3Cys (100 ng/ml) for 18 h. Cell supernatants were harvested, clarified and analyzed for cytokine
expression by ELISA. In all cases data are expressed as means ± SEM for 4 separate experiments. B. IL-6 expression (*p < 0.001, **p < 0.05). C.
IL-23 expression (*p < 0.001; **p = 0.002). D. TNFa expression (compared to PBS *p < 0.001; compared to GC frass **p = 0.023).
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Page 8 of 14cytokine production was also reduced in mice sensitized
with PAR-2-deficient BMDCs compared to wild type GC
frass-pulsed BMDCs, the effect was comparatively mild
(~10% reduction). There was no effect of adoptive transfer
of allergen-pulsed PAR-2-deficient BMDC on IFNg com-
pared to allergen-pulsed wild type BMDC, suggesting that
P A R - 2o nm D C si si m p o r t a n ti nd r i v i n gT h 2r e s p o n s e s ,
but has limited impact on Th1 or Th17 responses. More-
over, while adoptive transfer of GC frass-pulsed mDCs
from both wild type and PAR-2-deficient BMDC increased
eosinophil, neutrophil, and lymphocyte infiltration in to
the airways compared to PBS-pulsed DCs (Table 2), GC
frass-pulsed PAR-2-deficient BMDC induced significantly
less infiltration of eosinophils compared to GC-frass-
pulsed wild-type BMDC. Mucin production was increased
in the lungs of mice administered GC frass-pulsed wild
type BMDC compared to mice that received GC frass-
pulsed PAR-2-deficient BMDC (Figure 7). Administration
of GC frass to either completely naïve animals or mice
sensitized with PBS-pulsed BMDCs failed to initiate AHR
or Th2 cytokine skewing (data not shown), suggesting the
importance of the DC in the initiation of the allergic air-
way response, and suggesting repetition of allergen expo-
sure is important. These data suggest that protease
activation of PAR-2 on BMDC can modulate the immune
response and lead to the development of allergic airway
inflammation.
Discussion
Herein we describe a mechanism whereby serine pro-
teases promote the development of allergen-induced
AHR through activation of PAR-2. Confirming our pre-
v i o u sw o r k[ 1 3 ] ,a n dt h a to fo t h e r s[ 2 9 ]w ea g a i n
demonstrate that mucosal sensitization to GC frass is
reduced in mice lacking PAR-2, resulting in reduced
AHR and airway inflammation. Previous studies have
Figure 5 Co-stimulatory molecule expression in wild type and PAR-2-deficient mice following exposure to GC frass. BALB/c and PAR-
2-/- mice were administered a single intratracheal inhalation of PBS (40 μl) or GC frass (40 μg/40 μl) and whole lungs were isolated 20 h later.
Cells were dissociated from the lungs, and stained for flow cytometry analysis. mDC populations were analyzed for CD86 and CD80 expression.
Mean fluorescent intensity (MFI) of CD80 (A) and CD86 (B) and percentage of cells expressing CD80 (B) and CD86 (D) are shown. Values are
means ± SEM, n = 8 mice/group and statistical analysis was performed by ANOVA (*p < 0.001, **p < 0.05).
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Page 9 of 14Figure 6 Adoptive transfer of GC frass-pulsed PAR-2-deficient mDCs had attenuated airway responses compared to GC frass-pulsed
wild type mDCs. Naïve mice were sensitized with PBS- or GC frass-pulsed BMDC from wild type or PAR-2-/- mice on day 0. Mice were
challenged with PBS (40 μl) or GC frass (40 μg/40 μl) on day 14. On day 17, mice were anesthetized and acetycholine was injected after
establishment of a stable airway pressure. In all cases, means ± SEM are reported (n = 4-6 mice/group) and statistical analysis was performed by
ANOVA. A. AHR was measured as airway pressure time index (APTI) in cm-H2O × sec
-1 (* p < 0.001; **p = 0.003). Lungs from the mice were
excised; cells dissociated and maintained in a single suspension culture for 3 days in the presence of GC frass (1 μg/ml). Cell supernatants were
collected, clarified and analyzed by ELISA (in all cases *p < 0.001, *p < 0.05). B. IL-13 levels. C. IL-5 levels. D. IL-17A levels. E. IFNg levels.
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Page 10 of 14focused on the role for PAR-2 in direct activation of
bronchial epithelial cells [20,30-32] triggering the devel-
opment of innate immunity by causing the release of
chemotactic factors specific for the growth and
recruitment of pulmonary mDCs (i.e. CCL20, GM-CSF).
We demonstrate here that in vivo PAR-2-deficient mice
display reduced production of both Th2 and Th17-asso-
ciated cytokines, suggesting that PAR-2 differentially
Table 2 Differential cell count in BAL fluid from wild type and PAR2-deficient mice adoptively transferred with mDCs
pulsed with PBS or GC frass
Mac Epi Eos Neut Lymph
BALB/c DC PBS 2.2 ± 0.8 13.0 ± 3.5 0 0.1 ± 0.06 0.3 ± 0.2
PAR2-/- DC PBS 3.5 ± 1.3 14.3 ± 2.8 0 0.1 ± 0.03 0.2 ± 0.05
BALB/c DC frass 5.2 ± 2.1 9.8 ± 2.1 1.6 ± 0.4 9.5 ± 2.1 * 3.4 ± 0.5
PAR2-/- DC frass 3.8 ± 1.4 12.8 ± 3.5 0.7 ± 0.2 † 7.5 ± 1.6 * 3.0 ± 0.4
Bone marrow was isolated from BALB/c and PAR-2-/- mice and was cultured in the presence of GM-CSF for 6 days. Cells were pulsed with PBS or GC frass (1 μg/
ml) for an additional 24 hours. Wild type mice were sensitized to wild type and PAR-2-/- BMDC (1 × 10
6 cells) pulsed with PBS or GC frass on Day 0. Fourteen
days later, mice were challenged with an exposure to PBS or GC frass (40 μg/40 μl). On day 17, BAL fluid was harvested and differential cell counts performed.
These data represent 8 mice per group and are expressed as mean ± SEM of cell number × 10
3. Cell counts were statistically significant between GC frass-pulsed
BMDC and PBS-pulsed BMDC (*p < 0.05) and between GC frass-pulsed wild type BMDC and GC frass-pulsed PAR-2-/- BMDC (†p = 0.015).
Figure 7 Histological assessment of lung sections. Naïve mice were sensitized with PBS- or GC frass-pulsed BMDC from wild type or PAR-2-/-
mice on day 0. Mice were challenged with PBS (40 μl) or GC frass (40 μg/40 μl) on day 14. On day 17, lungs were isolated and fixed in formalin.
Periodic Acid Schiff (PAS) staining of sectioned lungs from mice exposed to PBS-pulsed wild type BMDCs (A) or GC frass-pulsed wild type BMDCs
(B). PAR-2-/- BMDC exposed to PBS (C) or GC frass (D) are also shown. Representative slides are shown of sections from 4-6 mice per group.
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Page 11 of 14influences multiple T cell responses. As mucosal expo-
sure to GC frass induces upregulation of PAR-2 on pul-
monary mDCs, but not pDCs, we sensitized naïve mice
with GC-frass pulsed wild type BMDCs, or BMDCs
from PAR-2-deficient mice. As previously observed [18],
the adoptive transfer of allergen-pulsed mDCs yields
robust production of IFNg and IL-17A and airway neu-
trophilia along with the typical Th2 cytokines and eosi-
nophilia, a response which more closely resembles the
mixed Th1/Th2/Th17 response observed in severe asth-
matics. However, in this context, the lack of PAR-2 on
sensitizing DCs markedly impacts Th2 cytokine produc-
tion, providing evidence that PAR-2 on mDCs is
involved in promoting Th2 immune responses. In con-
trast, the Th17 response is only slightly diminished in
mice sensitized with PAR-2-deficient DCs suggesting
that PAR-2 expression on other cell types controls Th17
cytokine production. Thus, the present study suggests
that specifically targeting PAR-2 activation of pulmonary
mDCs may allow one to limit the development of Th2
responses at mucosal sites.
The observation that the induction of Th2 responses by
GC frass is reduced in both PAR-2 deficient mice and mice
sensitized with PAR-2 deficient DCs strongly implicates
PAR-2 expression on mDCs on the ability of GC frass to
induce a Th2-polarized immune response at mucosal sur-
faces. However, the mechanism whereby PAR-2 promotes
the development of Th2 responses is unclear. While we
observed that PAR-2 deficient BMDCs produce signifi-
cantly reduced levels of all cytokines examined (IL-6,
IL-23, TNFa) we have previously reported that GC frass-
induced production of both IL-6 and IL-23 is completely
abrogated in MyD88 -/- BMDC [33], suggesting that PAR-
2 expression may amplify TLR-triggered cytokine produc-
tion. However, as LPS-depleted serine proteases still
demonstrated marked Th2-skewing capacity in vivo,i t
seems unlikely that the reduced Th2-skewing capacity of
PAR-2 DCs is the direct result of reduced cytokine produc-
tion. In contrast, PAR-2 activation has been shown to
enhance maturation of BMDCs (as evidenced by increased
MHC Class II and CD86 expression) [34], suggesting that
reduced co-stimulatory molecule expression may be
involved. In support of this possibility, we observe
decreased expression of the co-stimulatory molecule CD80
and CD86 on pulmonary mDCs from PAR-2 -/- mice. Col-
lectively, these data suggest that PAR-2 expression on pul-
monary mDCs is required for optimal induction of Th2
immunity following exposure to GC frass.
While our data suggests that DCs lacking PAR-2
demonstrate reduced Th2 skewing capacity we cannot
completely rule out a role for the epithelium in the ability
of the GC frass to induce a Th2 response. Epithelial cells
treated with allergens with active proteases (Aspergillus
extract, Derp1) induce IL-25, a strong inducer of Th2
immunity [35] in an ERK/p38 dependent manner [32].
As we have shown that GC protease mediated induction
of IL-8 from epithelial cells is dependent upon ERK acti-
vation [31], it is likely that IL-25 may also be produced.
Moreover, Alternaria mediated PAR-2 cleavage has also
been shown to induce TSLP production from bronchial
epithelial cells [30]. TSLP in turn directly enhances the
ability of DCs to induce a Th2 response [36,37], suggest-
ing an additional mechanism whereby PAR-2 may
amplify Th2 immunity. However, additional studies mak-
ing use of mice lacking PAR-2 specifically in DC popula-
tions or pulmonary epithelial cells will be required to
conclusively determine the relative contributions of PAR-
2 on DCs and epithelial cells.
It is interesting to note that while there is a substantial
(~75%) decrease in the number of neutrophils in the
BAL in PAR-2 -/- mice, a dramatic impact on neutrophil
recruitment was not observed in mice sensitized with GC
frass-pulsed PAR-2 -/- BMDCs (~20% decrease). This is
especially striking given that in both PAR-2 -/- and mice
sensitized with GC frass-pulsed PAR-2 -/- BMDCs levels
of IL-17A are only partially affected. As IL-17A is a
strong promoter of neutrophilia, this is somewhat sur-
prising. However, a recent report by Fei et al suggests
that elevated IL-17A is not sufficient to drive neutrophilia
in a model of allergic bronchopulmonary aspergilliosis
[38]. Rather, a combination of both TNFa and IL-17A
are required to get maximal neutrophil recruitment,
whereas the production of IL-17A alone was associated
with a more pronounced eosinophilia [38]. In this report
we also demonstrate that PAR-2 expression on mDCs is
required for maximal GC frass-induced production of
TNFa, suggesting that differential TNFa production may
explain differences in neutrophilia observed PAR-2 -/-
versus mice sensitized with GC frass-pulsed PAR-2 -/-
BMDCs. Indeed, in PAR-2 -/- mice, GC frass sensitiza-
tion results in limited IL-5, but robust IL-17A produc-
tion. Moreover, at challenge, PAR-2 -/- mice also lack
DC-derived, GC frass-stimulated TNFa production
resulting in a milieu with low IL-5 and TNFa,b u th i g h
IL-17A levels that is not conducive to strong recruitment
of eosinophils or neutrophils. In contrast, while sensitiza-
tion of mice with GC frass-pulsed BMDCs also results in
a low IL-5 and high IL-17A levels, GC frass challenge of
these mice induces high levels of TNFa as endogenous
DCs can respond to serine protease in the GC frass. This
resulted in a low IL-5, high TNFa/IL-17A milieu which
permits neutrophil recruitment, but resulted in limited
recruitment of eosinophils.
The data presented here suggest that the initial response
to inhaled GC frass is complex, and that synergy between
different components is likely required for maximal aller-
genic capacity. However, these studies do highlight the
importance of protease activity and activation of PAR-2
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Page 12 of 14receptors on pulmonary mDCs in inducing the develop-
ment of Th2 responses at mucosal surfaces. Taken
together with a number of other studies showing the abil-
ity of proteases to induce the development of Th2
responses [30,32,39], these studies suggest that activity of
proteases at mucosal surfaces may be a key factor regulat-
ing the development of Th2 immune responses. It is
important to note that while there is good evidence to
support that cockroach proteases and PAR-2 are involved
in the Th2 responses in the airways, this study does not
demonstrate the development of antigen-specific T cell
responses by cockroach proteases and PAR-2. A greater
understanding of the processes that lead to the develop-
ment of Th2 responses may prove invaluable in therapeu-
tic regulation of Th2 responses that are both undesirable
(i.e. allergy, asthma), or desirable (parasitic clearance).
Conclusions
The present study highlights the importance of func-
tional PAR-2 on mDCs as critical for the development of
Th2-biased immune response and indicates the mechan-
ism by which allergen-derived proteases initiate allergic
airway responses.
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